当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Modern Approaches for Treating Neonatal Jaundice: A Review

Hafeez Khan

Neonatal jaundice, characterized by the yellowing of an infant’s skin and eyes due to elevated bilirubin levels, is a common condition affecting newborns worldwide. This abstract provides a concise overview of the current knowledge and management strategies for neonatal jaundice.

Epidemiology: Neonatal jaundice affects approximately 60% of term and 80% of preterm newborns. While often benign, severe hyperbilirubinemia can lead to neurotoxicity and long-term neurological deficits if left untreated.

Pathophysiology the main cause of neonatal jaundice is the immature liver’s inability to efficiently conjugate and excrete bilirubin. Hemolysis, blood group incompatibilities, and genetic factors also contribute to its development.

Clinical presentation: Jaundice typically appears within the first few days of life. Physical examination and bilirubin level measurement help determine the severity of jaundice. Early recognition is essential to prevent complications.

Management: Phototherapy is the primary treatment for neonatal jaundice, converting unconjugated bilirubin into a water-soluble form for excretion. Severe cases may require exchange transfusions. Monitoring bilirubin levels and addressing underlying causes are crucial aspects of management.

Timely identification of infants at risk for severe jaundice, especially those with hemolytic disorders, is challenging. Effective communication with parents regarding the condition’s benign nature and potential complications is essential.